Posted by Michael Wonder on 01 Jul 2023
Schedule of Pharmaceutical Benefits - 1 July 2023
1 July 2023 - The July 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The July issue of the Schedule includes a few major new/revised listings:
- Avatrombopag maleate (Doptelet) - new medicine
- Choriogonadotropin alfa (Ovidrel) - restriction change
- Finerenone (Kerendia) - new medicine
- Fluticasone propionate (Axotide Junior, Flixotide Junior) - restriction change
- Nirmatrelvir and ritonavir (Paxlovid) - restriction change
- Tocilizumab (Actemra) - restriction change
